LAPTM4B在子宫内膜癌组织中表达及临床意义
|
摘要
目的探讨LAPTM4B在子宫内膜癌组织中的表达及临床意义。方法选取2011年3月至2013年3月鄂东医疗集团黄石市妇幼保健院行手术治疗的子宫内膜癌患者76例,同期,选取正常子宫内膜组织40例作为对照组,免疫组化法检测子宫内膜癌和对照组组织中LAPTM4B蛋白表达,所有患者均进行随访,随访截止日期2018年3月31日,随访过程中失访4例,随访率93.42%,生存分析采用Kaplan-Meier法和Log-Rank检验,影响患者预后的多因素分析采用Cox比例风险回归模型。结果子宫内膜癌组织中LAPTM4B蛋白阳性表达率为73.68%,高于对照组的27.50%,差异有统计学意义(χ~2=22.911,P <0.001);LAPTM4B蛋白表达在不同FIGO分期、不同分化程度和是否淋巴结转移差异有统计学意义(P <0.05);Kaplan-Meier生存分析结果显示,阳性表达组平均生存时间(42.76±4.16)个月,生存率33.96%,阴性表达组则分别为(71.53±4.78)个月和78.95%,Log-Rank检验差异有统计学意义(χ~2=10.458,P=0.001);Cox比例风险回归结果显示,分化程度、淋巴结转移和LAPTM4B蛋白表达是影响患者预后的因素(HR=0.436、5.993和3.052,P <0.05)。结论子宫内膜癌组织中LAPTM4B蛋白表达升高,且与肿瘤恶性进展有关及预后有关,是影响患者预后的危险因素。
Objective To investigate the expression and clinical significance of LAPTM4 B in endometrial carcinoma. Methods A total of 76 cases of patients with endometrial carcinoma who underwent surgery were selected in our hospital from March 2011 to March 2013. In the same period, 40 cases of normal endometrial tissues were selected as the control group. The expressions of LAPTM4 B proteins in endometrial carcinoma and control group tissues were detected by immunohistochemistry. All patients were followed up, and the follow-up deadline was March 31, 2018. Four patients were lost during the follow-up period, and the follow-up rate was 93.42%. Survival analysis was using Kaplan-Meier method and Log-Rank test. Multivariate analysis of factors affecting patient prognosis was using Cox proportional hazard regression model. Results The positive expression rate of LAPTM4 B protein in endometrial carcinoma tissues was 73.68%, which was higher than that in control group(27.50%), the difference was statistically significant(χ~2= 22.911,P < 0.001). The differences of the expression of LAPTM4 B proteins in different FIGO stages, different degrees of differentiation and lymph node metastasis were statistically significant(P < 0.05). Kaplan-Meier survival analysis showed that the average survival time in the positive expression group was(42.76±4.16) months, the survival rate was 33.96%, while in the negative expression group were(71.53 ±4.78) months and 78.95%, respectively, Log-Rank test showed the difference was statistically significant(χ~2= 10.458, P = 0.001). Cox proportional hazards regression showed that the degree of differentiation, lymph node metastasis and LAPTM4 B protein expression were factors influencing the prognosis of patients(HR=0.436, 5.993 and 3.052, P < 0.05). Conclusions The expression of LAPTM4 B protein in endometrial carcinoma tissues is upregulated, and is related to the malignant progression of the tumor and the prognosis. It is a risk factor affecting the prognosis of patients.
Objective To investigate the expression and clinical significance of LAPTM4 B in endometrial carcinoma. Methods A total of 76 cases of patients with endometrial carcinoma who underwent surgery were selected in our hospital from March 2011 to March 2013. In the same period, 40 cases of normal endometrial tissues were selected as the control group. The expressions of LAPTM4 B proteins in endometrial carcinoma and control group tissues were detected by immunohistochemistry. All patients were followed up, and the follow-up deadline was March 31, 2018. Four patients were lost during the follow-up period, and the follow-up rate was 93.42%. Survival analysis was using Kaplan-Meier method and Log-Rank test. Multivariate analysis of factors affecting patient prognosis was using Cox proportional hazard regression model. Results The positive expression rate of LAPTM4 B protein in endometrial carcinoma tissues was 73.68%, which was higher than that in control group(27.50%), the difference was statistically significant(χ~2= 22.911,P < 0.001). The differences of the expression of LAPTM4 B proteins in different FIGO stages, different degrees of differentiation and lymph node metastasis were statistically significant(P < 0.05). Kaplan-Meier survival analysis showed that the average survival time in the positive expression group was(42.76±4.16) months, the survival rate was 33.96%, while in the negative expression group were(71.53 ±4.78) months and 78.95%, respectively, Log-Rank test showed the difference was statistically significant(χ~2= 10.458, P = 0.001). Cox proportional hazards regression showed that the degree of differentiation, lymph node metastasis and LAPTM4 B protein expression were factors influencing the prognosis of patients(HR=0.436, 5.993 and 3.052, P < 0.05). Conclusions The expression of LAPTM4 B protein in endometrial carcinoma tissues is upregulated, and is related to the malignant progression of the tumor and the prognosis. It is a risk factor affecting the prognosis of patients.
引文
[1]于秀章,侯敏敏.子宫内膜癌前哨淋巴结检测研究现状[J].实用妇产科杂志,2018,34(5):344-347.
[2]DOGHRI R,CHAABOUNI S,HOUCINE Y,et al. Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer[J]. Mol Clin Oncol,2018,9(1):87-91.
[3]党勇,段钊.CT联合MRI子宫内膜癌分期诊断与术后VEGF-C水平观察[J].昆明医科大学学报,2017,38(6):124-129.
[4]MENG Y,WANG L,CHEN D,et al. LAPTM4B:an oncogene in various solid tumors and its functions[J].Oncogene,2016,35(50):6359-6365.
[5]杨洋. LAPTM4B基因多态性与人类肿瘤的关系[J].实用肿瘤学杂志,2013,27(2):172-176.
[6]LEWIN S N,HERZOG T J,BARRENA MEDEL N I,et al.Comparative performance of the 2009 international Federation of gynecology and obstetrics'staging system for uterine corpus cancer[J]. Obstet Gynecol,2010,116(5):1141-1149.
[7]张静怡,单丽珠,张洁,等. LAPTM4B-35和MMP-9在胃癌中表达及临床意义[J].中国肿瘤临床,2017,44(24):1226-1231.
[8]高静,项永兵.哺乳与子宫内膜癌关系的流行病学研究进展[J].中国肿瘤临床,2018,45(1):42-46.
[9]CONNOR E V,ROSE P G. Management strategies for recurrent endometrial cancer[J]. Expert Rev Anticancer Ther,2018,18(9):873-885.
[10]BRAUN M M,OVERBEEK-WAGER E A,GRUMBO R J. Diagnosis and management of endometrial cancer[J].Am Fam Physician,2016,93(6):468-474.
[11]MENG Y,WANG L,CHEN D,et al. LAPTM4B:an oncogene in various solid tumors and its functions[J].Oncogene,2016,35(50):6359-6365.
[12]MENG F,TAN S,LIU T,et al. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer[J]. Tumour Biol, 2016, 37(4):4849-4855.
[13]KONG F,GAO F,CHEN J,et al.Overexpressed LAPTM4B35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer[J]. Oncotarget,2016,7(35):56193-56199.
[14]MENG Y,WANG L,XU J,et al. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis,while reducing chemotherapy sensitivity[J].Mol Oncol,2018,12(3):373-390.
[2]DOGHRI R,CHAABOUNI S,HOUCINE Y,et al. Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer[J]. Mol Clin Oncol,2018,9(1):87-91.
[3]党勇,段钊.CT联合MRI子宫内膜癌分期诊断与术后VEGF-C水平观察[J].昆明医科大学学报,2017,38(6):124-129.
[4]MENG Y,WANG L,CHEN D,et al. LAPTM4B:an oncogene in various solid tumors and its functions[J].Oncogene,2016,35(50):6359-6365.
[5]杨洋. LAPTM4B基因多态性与人类肿瘤的关系[J].实用肿瘤学杂志,2013,27(2):172-176.
[6]LEWIN S N,HERZOG T J,BARRENA MEDEL N I,et al.Comparative performance of the 2009 international Federation of gynecology and obstetrics'staging system for uterine corpus cancer[J]. Obstet Gynecol,2010,116(5):1141-1149.
[7]张静怡,单丽珠,张洁,等. LAPTM4B-35和MMP-9在胃癌中表达及临床意义[J].中国肿瘤临床,2017,44(24):1226-1231.
[8]高静,项永兵.哺乳与子宫内膜癌关系的流行病学研究进展[J].中国肿瘤临床,2018,45(1):42-46.
[9]CONNOR E V,ROSE P G. Management strategies for recurrent endometrial cancer[J]. Expert Rev Anticancer Ther,2018,18(9):873-885.
[10]BRAUN M M,OVERBEEK-WAGER E A,GRUMBO R J. Diagnosis and management of endometrial cancer[J].Am Fam Physician,2016,93(6):468-474.
[11]MENG Y,WANG L,CHEN D,et al. LAPTM4B:an oncogene in various solid tumors and its functions[J].Oncogene,2016,35(50):6359-6365.
[12]MENG F,TAN S,LIU T,et al. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer[J]. Tumour Biol, 2016, 37(4):4849-4855.
[13]KONG F,GAO F,CHEN J,et al.Overexpressed LAPTM4B35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer[J]. Oncotarget,2016,7(35):56193-56199.
[14]MENG Y,WANG L,XU J,et al. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis,while reducing chemotherapy sensitivity[J].Mol Oncol,2018,12(3):373-390.